Investigation of a metabolism-dependent aryl hydrocarbon receptor off-target activation for a drug development candidate and a screening strategy for de-risking backups
Toxicological Sciences · 01.08.2026 · 209 (8)
DOI: 10.1093/toxsci/kfag083 ↗Kurz gefasst
Fachartikel in der Zeitschrift Toxicological Sciences, online erschienen am 20.07.2026. Verfasst von Amy G Aslamkhan und 26 weiteren Autor:innen. Beteiligte Einrichtung: Nonclinical Drug Safety, Merck & Co., Inc., Rahway, NJ 07065, United States. Hauptthemen laut MEDLINE: Receptors, Aryl Hydrocarbon, Basic Helix-Loop-Helix Proteins, Drug Discovery. Die Arbeit nennt 27 Literaturangaben.
Abstract (Originalsprache)
During lead optimization, off-target activation of the aryl hydrocarbon receptor (AhR) was identified for Compound 25. AhR is a xenobiotic-responsive transcription factor associated with adverse outcomes in rodents (and potentially humans) and modulation of drug metabolism. In rats, marked hepatic induction of AhR target genes, Cyp1a1 and Cyp1a2, was observed following repeat dosing and increased with study duration. Compound 25 was inactive in conventional AhR luciferase reporter assays but induced robust Cyp1a1 expression in metabolically competent rat and human HEPATOPAC cultures, suggesting a metabolism-dependent mechanism. Extensive metabolite profiling demonstrated that Compound 25 undergoes complex oxidative and conjugative metabolism; however, specific AhR-active metabolite(s) could not be identified. AhR involvement was confirmed in vivo using AhR knockout and wild-type rats, in which Cyp1a1/2 induction occurred exclusively in wild-type animals. Chromatin immunoprecipitation further demonstrated increased AhR binding at Cyp1a1/2 promoters following Compound 25 treatment. In rat HEPATOPAC cultures, siRNA-mediated knockdown of Por and Cyb5a attenuated Cyp1a1 induction, supporting a requirement for metabolic competence. Consistent with AhR pathway engagement, induction of CYP1A1 in human HEPATOPAC was reduced by the AhR antagonist CH223191. Collectively, these findings demonstrate that AhR activation associated with Compound 25 is dependent on metabolic transformation and may not be detected in conventional reporter assays lacking metabolic capacity. This work highlights the value of metabolically competent hepatocyte models, combined with short-duration in vivo studies, for identifying and mitigating metabolism-dependent AhR liabilities during drug discovery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nonclinical Drug Safety, Merck & Co., Inc., Rahway, NJ 07065, United States.
- Pharmacokinetics, Dynamics, Metabolism and Bioanalytics, Merck & Co., Inc., Rahway, NJ 07065, United States.
- Data, AI and Genome Sciences, Merck & Co., Inc., Rahway, NJ 07065, United States.
- Department of Chemistry, Massachusetts Institute of Technology, Boston, MA 02139, United States.
- Chemistry, Merck & Co., Inc., Rahway, NJ 07065, United States.
- Neuroscience Discovery, Merck & Co., Inc., Rahway, NJ 07065, United States.
ORCID-Profile: Amy G Aslamkhan, Kara M Pearson
Zitieren
APA
Aslamkhan, A. G., Kang, W., Otte, K., Tamburino, A., Ciaccio, P. J., Sacre-Salem, B., Erdos, Z., Liang, Y., Gundersdorf, R. W., Becker, B., Tanis, K. Q., Pippert, T., Lane, P., Jacob, B., Bleicher, K. B., Wang, Z., Su, M., Pacchione, S., Candito, D., …, & Glaab, W. E. (2026). Investigation of a metabolism-dependent aryl hydrocarbon receptor off-target activation for a drug development candidate and a screening strategy for de-risking backups. Toxicological Sciences, 209(8). https://doi.org/10.1093/toxsci/kfag083
Vancouver
Aslamkhan AG, Kang W, Otte K, Tamburino A, Ciaccio PJ, Sacre-Salem B, et al. Investigation of a metabolism-dependent aryl hydrocarbon receptor off-target activation for a drug development candidate and a screening strategy for de-risking backups. Toxicological Sciences. 2026;209(8). doi:10.1093/toxsci/kfag083
BibTeX
@article{Aslamkhan2026,
author = {Aslamkhan, Amy G and Kang, Wen and Otte, Karin and Tamburino, Alex and Ciaccio, Paul J and Sacre-Salem, Beatrice and Erdos, Zoltan and Liang, Yuexia and Gundersdorf, Richard W and Becker, Bridget and Tanis, Keith Q and Pippert, Todd and Lane, Pam and Jacob, Binod and Bleicher, Kimberly B and Wang, Zhibin and Su, Ming and Pacchione, Stephen and Candito, David and Simov, Vladimir and Fuller, Peter H and Fell, Matthew J and Ellis, J Michael and Foti, Robert and Pearson, Kara M and Sistare, Frank D and Glaab, Warren E},
title = {Investigation of a metabolism-dependent aryl hydrocarbon receptor off-target activation for a drug development candidate and a screening strategy for de-risking backups},
journal = {Toxicological Sciences},
year = {2026},
volume = {209},
number = {8},
doi = {10.1093/toxsci/kfag083}
}
EUVIMED